MX2022003845A - Tratamientos cognitivos medicinales. - Google Patents
Tratamientos cognitivos medicinales.Info
- Publication number
- MX2022003845A MX2022003845A MX2022003845A MX2022003845A MX2022003845A MX 2022003845 A MX2022003845 A MX 2022003845A MX 2022003845 A MX2022003845 A MX 2022003845A MX 2022003845 A MX2022003845 A MX 2022003845A MX 2022003845 A MX2022003845 A MX 2022003845A
- Authority
- MX
- Mexico
- Prior art keywords
- medicinal
- healthy subject
- cognitive
- treatments
- cognitively healthy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019903681A AU2019903681A0 (en) | 2019-09-30 | Medicinal cognitive treatments | |
| PCT/AU2020/051043 WO2021062472A1 (en) | 2019-09-30 | 2020-09-30 | Medicinal cognitive treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022003845A true MX2022003845A (es) | 2022-06-22 |
Family
ID=75336310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022003845A MX2022003845A (es) | 2019-09-30 | 2020-09-30 | Tratamientos cognitivos medicinales. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230000843A1 (enExample) |
| EP (1) | EP4037684A4 (enExample) |
| JP (1) | JP2022550221A (enExample) |
| KR (1) | KR20220080116A (enExample) |
| CN (1) | CN114761005A (enExample) |
| AU (1) | AU2020359291B2 (enExample) |
| CA (1) | CA3152902A1 (enExample) |
| CL (1) | CL2022000781A1 (enExample) |
| IL (1) | IL292739B2 (enExample) |
| MX (1) | MX2022003845A (enExample) |
| WO (1) | WO2021062472A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI855081B (zh) * | 2019-05-24 | 2024-09-11 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| IL303170A (en) * | 2020-11-25 | 2023-07-01 | Sage Therapeutics Inc | 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders |
| WO2024073794A1 (en) * | 2022-10-07 | 2024-04-11 | Actinogen Medical Limited | SUBJECT SELECTION FOR 11β-HSD1 INHIBITOR TREATMENT |
| CN121969372A (zh) * | 2023-10-03 | 2026-05-01 | 射线质医疗有限公司 | 片剂制剂 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2477983T3 (en) * | 2009-09-16 | 2015-06-29 | Univ Edinburgh | (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE |
| BR112012027640B1 (pt) * | 2010-04-29 | 2021-08-03 | The University Of Edinburgh | Composto, composição farmacêutica, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 |
-
2020
- 2020-09-30 EP EP20870933.7A patent/EP4037684A4/en active Pending
- 2020-09-30 AU AU2020359291A patent/AU2020359291B2/en active Active
- 2020-09-30 JP JP2022544867A patent/JP2022550221A/ja active Pending
- 2020-09-30 CA CA3152902A patent/CA3152902A1/en active Pending
- 2020-09-30 CN CN202080082617.6A patent/CN114761005A/zh active Pending
- 2020-09-30 US US17/764,922 patent/US20230000843A1/en active Pending
- 2020-09-30 WO PCT/AU2020/051043 patent/WO2021062472A1/en not_active Ceased
- 2020-09-30 KR KR1020227014330A patent/KR20220080116A/ko not_active Ceased
- 2020-09-30 MX MX2022003845A patent/MX2022003845A/es unknown
-
2022
- 2022-03-29 CL CL2022000781A patent/CL2022000781A1/es unknown
- 2022-05-03 IL IL292739A patent/IL292739B2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022000781A1 (es) | 2022-11-18 |
| CN114761005A (zh) | 2022-07-15 |
| WO2021062472A1 (en) | 2021-04-08 |
| AU2020359291B2 (en) | 2026-04-30 |
| US20230000843A1 (en) | 2023-01-05 |
| KR20220080116A (ko) | 2022-06-14 |
| JP2022550221A (ja) | 2022-11-30 |
| AU2020359291A1 (en) | 2022-04-21 |
| EP4037684A1 (en) | 2022-08-10 |
| CA3152902A1 (en) | 2021-04-08 |
| IL292739B2 (en) | 2026-08-01 |
| IL292739B1 (en) | 2026-04-01 |
| EP4037684A4 (en) | 2023-11-01 |
| IL292739A (en) | 2022-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| WO2020033838A3 (en) | Treatment of egfr-mutant cancer | |
| CL2022000781A1 (es) | Tratamientos cognitivos medicinales | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| ECSP22089498A (es) | Inhibidores de il4i1 y métodos de uso | |
| MX2024005107A (es) | Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer. | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| JOP20190086A1 (ar) | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب | |
| PH12023550780A1 (en) | Line-1 inhibitors to treat disease | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| ZA202102241B (en) | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| MX2023014898A (es) | Terapia combinada anti-vhc ventajosa. | |
| MX2023009620A (es) | Metodos terapeuticos. | |
| MX2021002590A (es) | Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor. | |
| EA202192234A1 (ru) | Комбинированная терапия для применения в лечении рака | |
| BR112022005980A2 (pt) | Método para prevenir e/ou tratar declínio cognitivo em um sujeito cognitivamente saudável, composto, e, uso de um composto | |
| PH12020551620A1 (en) | Compositions for preventing or treating dry eye | |
| MY206505A (en) | Therapeutic agent for glaucoma comprising fp agonist and -blocker |